On Monday, Shares of Twilio Inc (NYSE:TWLO), subtract -14.13% and closed at $52.02 in the last trading session. The last trading range of the stock ranges between $51.39 and $58.91. The company’s Market capitalization is $4.39 Billion with the total Outstanding Shares of 84.57 Billion. During the 52-week trading session the minimum price at which share price traded, registered at $23.66 and reached to max level of $70.96. Twilio Inc. (TWLO), a leading Cloud Communications Platform company, recently declared that it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) regardinga projected follow-on public offering of shares of its Class A common stock. A majority of the shares in the projected offering are expected to be sold by existing stockholders. Twilio will not receive any proceeds from the sale of the shares by the selling stockholders. The number of shares of Class A common stock to be sold and the allocation of the shares between Twilio and existing stockholders has not yet been determined.
Goldman, Sachs & Co. and J.P. Morgan Securities LLC will act as joint book-running managers for the projected offering. Allen & Company LLC; Pacific Crest Securities, a division of KeyBanc Capital Markets Inc.; JMP Securities LLC; William Blair & Company, L.L.C.; and Canaccord Genuity Inc. will act as co-managers.
Endo International plc – Ordinary Shares (NASDAQ:ENDP), jumped 3.98% and closed at $21.18 in the last trading session. The last trading range of the stock ranges between $20.52 and $21.66. During the 52-week trading session the minimum price at which share price traded, registered at $12.56 and reached to max level of $69.33. Endo Pharmaceuticals Inc., a partner of Endo International plc (ENDP) (ENL.TO), recently declared new data to be presented evaluating the safety and efficacy of XIAFLEX®(collagenase clostridium histolyticum) (or CCH) injection under investigation for the treatment of palmar Dupuytren’s disease nodules. The findings will be presented during a podium presentation on Saturday, October 1, 2016 at 10:40 a.m. CDT at the annual meeting of the American Society for Surgery of the Hand (ASSH) held from September 29 to October 1, 2016 in Austin, Texas.
In a Phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, in 75 adult study participants with Dupuytren’s disease and at least 1 nodule who received a single injection of CCH 0.40 mg or 0.60 mg, a statistically noteworthydecrease was shown from baseline in the mean nodule surface area (P≤0.001), consistency score (P<0.001) and hardness score (P≤0.01) at week 8 as compared to study participants receiving placebo. The safety profile of those treated with CCH was generally well tolerated. Adverse events included extremity pain, axillary pain, injection site-related adverse events and pruritus. One adverse event was stated as severe (injection site pain with CCH 0.60 mg). No patients were suspended from the study because of an adverse event.